Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Evolent Health, Inc. of $125 million aggregate principal amount of its 2.00% senior convertible notes due 2021, which included $15 million aggregate principal amount of notes issued pursuant to the full exercise of the initial purchasers’ option to purchase additional notes.

Based in Arlington, Virginia, Evolent Health partners with leading health systems to drive value-based care transformation. By providing clinical, analytical and financial capabilities, Evolent Health helps physicians and health systems achieve superior quality and cost results. Evolent Health’s approach breaks down barriers, aligns incentives and powers a new model of care delivery, resulting in meaningful alignment between providers, payers, physicians and patients.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Yasin Keshvargar and John H. Runne. The equity derivatives team included partner John M. Brandow and associate Barry J. Gewolb. Partner Pritesh P. Shah and associate Gregory R. Baden provided intellectual property and technology advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post